Bharat Biotech Releases Long-Awaited Covaxin Phase 3 Data, Claims 77.8% Efficacy 03/07/2021
Union health minister Harsh Vardhan holds up a vial of Covaxin, AIIMS Delhi, January 16, 2021. Photo: Reuters/Adnan Abidi/File Photo
New Delhi: Even as its Brazil deal has gone belly-up, with the company staring at two criminal investigations into its attempt to import Covaxin into the South American country, Bharat Biotech has released the preprint paper describing the phase 3 trials of the beleaguered vaccine.
The company said in a statement that Covaxin demonstrated an efficacy of 77.8% in the trials.
“I am delighted to note that Covaxin developed by ICMR and BBIL, under an effective public-private partnership, has demonstrated an overall efficacy of 77.8% in India’s largest COVID-19 phase 3 clinical trial thus far,” Indian Council of Medical Research (ICMR) director-general Dr Balram Bhargava told
Bharat Biotech Releases Long-Awaited Covaxin's Phase 3 Trial Data, Claims 77.8% Efficacy thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewire.in Daily Mail and Mail on Sunday newspapers.
Even as questions remain on the efficacy of Ayurvedic medicines in the case of COVID-19, the ministry of AYUSH said it will distribute AYUSH 64 and Kabasura Kudineer medicines to out-of-hospital patients.